Last reviewed · How we verify
NCT01050296: MAST
Molecular Analysis Of Solid Tumors
trial in Pediatric Solid Tumors in 1,000 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | St. Jude Children's Research Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 10 February 2010 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across United States |
Conditions studied
- Pediatric Solid Tumors — all drugs for Pediatric Solid Tumors →
Sponsor
St. Jude Children's Research Hospital
Who can join
Under 25, any sex, with Pediatric Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will prospectively characterize the molecular, cellular and genetic properties of primary and metastatic neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma family of tumors, soft tissue sarcomas, adrenocortical tumors and liver malignancies. These cell isolates will be used for gene expression array analysis, genomic analysis by \[SNP\] single nucleotide polymorphism chip, array \[CGH\] comparative genomic hybridization and next generation sequencing, and \[TEM\] transmission electron microscopy analysis. Additionally cell lines and orthotopic xenografts will be created from the obtained tumor specimens. The specificity of TCRs will be examined by comparing paired TCR from peripheral blood and tumor infiltrating CD4+ and CD8+ T cells. Epigenetic studies will be performed looking at the methylation profile of these cells and to investigate the anti-tumor T cell response both pre- and post-PD1 inhibition.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Orthotopic patient-derived xenografts of paediatric solid tumours.
Stewart E, Federico SM, Chen X, Shelat AA, et al · · 2017 · cited 252× · PMID 28854174 · DOI 10.1038/nature23647 -
MicroRNAs and Potential Targets in Osteosarcoma: Review.
Sampson VB, Yoo S, Kumar A, Vetter NS, et al · · 2015 · cited 128× · PMID 26380245 · DOI 10.3389/fped.2015.00069 -
microRNA-based diagnostic and therapeutic applications in cancer medicine.
Sempere LF, Azmi AS, Moore A. · · 2021 · cited 97× · PMID 33998154 · DOI 10.1002/wrna.1662 -
Next generation sequencing in cancer research and clinical application.
Shyr D, Liu Q. · · 2013 · cited 73× · PMID 23406336 · DOI 10.1186/1480-9222-15-4 -
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
MicroRNAs in cancer therapeutics: "from the bench to the bedside".
Monroig-Bosque Pdel C, Rivera CA, Calin GA, Calin GA. · · 2015 · cited 34× · PMID 26372796 · DOI 10.1517/14712598.2015.1074999 -
Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.
Dyer MA. · · 2016 · cited 33× · PMID 27567287 · DOI 10.1016/j.molmed.2016.07.010 -
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 : National Harbor, MD, USA. 10 November 2019.
· 2019 · cited 25× · PMID 31694708 · DOI 10.1186/s40425-019-0764-0
Verify or expand the search:
- PubMed search for NCT01050296
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Solid Tumors
Currently open trials in the same condition.
- NCT06969742 — Development and Application of Intervention Program to Improve Mental Health and Quality of Life of Solid Tumor Survivor · NA · recruiting
- NCT07240207 — Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy · recruiting
- NCT05608148 — Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors · Phase 1 · recruiting
Other St. Jude Children's Research Hospital trials
Trials by the same sponsor.
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
- NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
- NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01050296 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
- Last refreshed: 12 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01050296.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing